IN RE PHARMACEUTICAL INDUSTRY

UNITED STATES DISTRICT COURT FOR THE DISTRICT OF MASSACHUSETTS

Case No. 02C 0396 (N.D. Illinois)	७१-१२३६८ ५७८
Hon. I atti D. Sans	

MOTION TO DISMISS

Defendant Fujisawa Pharmaceutical Co., Ltd. ("Fujisawa Pharmaceutical") was served by plaintiff Action Alliance of Senior Citizens of Greater Philadelphia ("Alliance") on April 22, 2002, pursuant to the applicable provisions of the Hague Convention. Fujisawa Pharmaceutical hereby moves this Court pursuant to Fed. R. Civ. P. 12(b)(6) to dismiss Alliance's Class Action Complaint (the "Complaint"). In support of the motion, Fujisawa Pharmaceutical states as follows:

- 1. Alliance brings this case as a purported class action alleging an antitrust violation under Section 2 of the Sherman Act.
- 2. The Complaint should be dismissed in its entirety pursuant to Rule 12(b)(6) because Alliance has not adequately pleaded (a) the existence of a relevant market, (b) that

03

Fujisawa Pharmaceutical has a monopoly power in that relevant market, or (c) an antitrust injury - all of which are essential elements of a cause of action under Section 2 of the Sherman Act. In addition, the Complaint should be dismissed because Alliance lacks standing.

3. As grounds for this motion, defendant Fujisawa Pharmaceutical relies upon the attached memoranda of law (Exhibit A) submitted by defendants Fujisawa Healthcare, Inc. and Fujisawa USA, Inc. in support of their earlier-filed motion to dismiss the Complaint as against them. The arguments set forth therein apply equally to defendant Fujisawa Pharmaceutical, and the Complaint should therefore be dismissed as against it as well.

WHEREFORE defendant Fujisawa Pharmaceutical respectfully requests that the Court dismiss the Complaint of plaintiff Alliance with prejudice.

RULE 7.1(A)(2) CERTIFICATION

In accordance with L.R. 7.1(A)(2), counsel for defendant Fujisawa Pharmaceutical, Sandra E. Grandison, certifies that she conferred with counsel for the plaintiff in good faith to resolve or narrow the issues presented by this motion.

REQUEST FOR ORAL ARGUMENT

In accordance with L.R. 7.1(D), defendant Fujisawa Pharmaceutical requests oral argument on this motion.

> FUJISAWA PHARMACEUTICAL CO., LTD.

By its attornéy,

Sandra E. Grandison BB0# 643763

BINGHAM DANA LLP

399 Park Avenue

New York, NY 10022-4689

(212) 318-7700

Dated: May 10, 2002

CERTIFICATE OF SERVICE

I hereby certify that a true copy of the above document was served upon the attorneys of record for each other party as listed below by U.S. Mail postage pre-paid on May 10, 2002.

Sandra E. Grandison

Kathleen H. McGuan Jacqueline E. Bennett **REED SMITH LLP** 1301 K Street, N.W. Suite 1100 – East Tower Washington, DC 20005 (202) 414-9200

Mary Ellen Hennessy Stephen D. Liowsky KATTEN MUCHIN ZAVIS 525 West Monroe Street **Suite 1600** Chicago, IL 60661 (312) 902-5200

Kenneth A. Wexler, Esquire Elizabeth Fegan Hartweg, Esquire KENNETH A WEXLER AND ASSOCIATES One North LaSalle **Suite 2000** Chicago, IL 60602

Daniel E. Gustafson, Esquire HEINS MILLS & OLSON, P.C. 700 Northstar East 608 Second Avenue South Minneapolis, MN 55402

Ira Neil Richard, Esquire RODRIGUEZ & RICHARDS, LLC The Penthouse 226 West Ritten House Square Philadelphia, PA 19103

Jonathan Shub, Esquire SHELLER, LUDWIG & BADLEY 1528 Walnut Street 3rd Floor Philadelphia, PA 19102

Marc H. Edelson, Esquire **HOFFMAN & EDELSON** 45 West Court Street Doylestown, PA 18901

Lee Squitieri, Esquire **SQUITIERI & FEARON** 521 Fifth Avenue 26th Floor New York, NY 10175

Anthony Bolognese, Esquire **BOLOGNESE & ASSOCIATES** One Penn Center 1617 JFK Boulevard, Suite 650 Philadelphia, PA 19103